|
|||||
|
|
Therapeutic potential of A2 adenosine receptor pharmacological regulators in the treatment of cardiovascular diseases,recent progress,and prospective |
|
| Authors: | Amirhossein Bahreyni Amir Avan Mohammad Shabani Mikhail Ryzhikov Hamid Fiuji Saman Soleimanpour Majid Khazaei Seyed Mahdi Hassanian |
| Institution: | 1. Department of Clinical Biochemistry and Immunogenetic Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran;2. Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran;3. Department of Medical Biochemistry, School of Medicine, Iran University of Medical Sciences, Tehran, Iran;4. Division of Pulmonary and Critical Care Medicine, School of Medicine, Washington University, St. Louis, Missouri;5. Department of Biochemistry, Payam-e-Noor University, Mashhad, Iran;6. Department of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran |
| Abstract: | Adenosine and its analogs are of particular interest as potential therapeutic agents for treatment of cardiovascular diseases (CVDs). A2 adenosine receptor subtypes (A2a and A2b) are extensively expressed in cardiovascular system, and modulation of these receptors using A2 adenosine receptor agonists or antagonists regulates heart rate, blood pressure, heart rate variability, and cardiovascular toxicity during both normoxia and hypoxia conditions. Regulation of A2 adenosine receptor signaling via specific and novel pharmacological regulators is a potentially novel therapeutic approach for a better understanding and hence a better management of CVDs. This review summarizes the role of pharmacological A2 adenosine receptor regulators in the pathogenesis of CVDs. |
| Keywords: | A2 adenosine receptor cardiovascular diseases pharmacological inhibitors |